Mirapex promotional violations cited

Share this article:
Two consumer-directed pharmacy printouts and a professionally directed labeling piece for Boehringer-Ingelheim's Mirapex were considered misleading, according to a warning letter from FDA's DDMAC. 

The letter said the consumer printouts presented Mirapex efficacy claims but failed to either communicate any risk information or to communicate the most important risks associated with Mirapex use. Also, the DDMAC wrote, it appeared that neither piece was accompanied by the FDA-approved product labeling. The professional piece presented efficacy claims but omitted material facts and broadened the drug's indication, according to the warning letter. DDMAC said the materials raised significant public health and safety concerns by suggesting that Mirapex is safer than has been demonstrated.

Mirapex's labeling said it is indicated for treating moderate-to-severe primary restless leg syndrome (RLS). The labeling lists warnings, including falling asleep during activities of daily living, symptomatic hypotension and hallucinations. 

The DDMAC letter described numerous efficacy claims in the consumer printouts. It said one of the printouts failed to present any risk information and the second failed to reveal important warnings. The DDMAC said a statement at the bottom of the two printouts telling consumers to see accompanying information was not sufficient. The professionally directed piece failed to present the approved Mirapex indication.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete October 2014 Digital Edition

Read the complete October 2014 Digital Edition

Click the above link to access the complete Digital Edition of the October 2014 issue of MM&M, with all text, charts and pictures.

Predicting your pink slip

Predicting your pink slip

Any time a firm needs to save money, high-salaried executives are targets

Private View: New ways to engage with customers

Private View: New ways to engage with customers

These healthcare social media campaigns successfully use emotion, altruism and the human desire to "brand" oneself to get customers engaged.